Share this Page:
Results from the phase 3 KEYNOTE-581/CLEAR trial show that the combination of pembrolizumab plus lenvatinib significantly improved the time taken for the cancer to start growing again (progression-free survival), overall survival, and the response rate compared with sunitinib, when used for untreated patients with advanced renal cell carcinoma (RCC).
The pembrolizumab/lenvatinib combination had similar side effects to what has previously been seen in other clinical trials.
In the trial, the safety and efficacy of lenvatinib in combination with everolimus (arm A), or pembrolizumab (arm B), versus sunitinib (arm C) were compared as first-line treatment in patients with advanced RCC. Around 1050 patients were enrolled to the trial and they were randomised to 1 of the 3 treatment arms.
